Clinical Trial Detail

NCT ID NCT02617849
Title Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Wilson Miller
Indications

melanoma

Therapies

Carboplatin + Paclitaxel + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.